SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Feb 7, 2007
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Feb. 7, 2007 · CIK: 0000921114 · Accession: 0001144204-07-005734
AI Filing Summary & Sentiment
File numbers found in text: 333-140187
Referenced dates: February 2, 2007
Letter
Division of Corporate Finance Securities and Exchange Commission Attention: Song P. Brandon, Esq Re: Targeted Genetics Corporation Registration Statement on Form S-3 File Number 333-140187
Dear Mr. Riedler:
This letter sets forth the response of Targeted Genetics Corporation, a Washington corporation (the “Company”), to the comments set forth in the Staff’s letter dated February 2, 2007 in connection with the Company’s Registration Statement on Form S-3 (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) on January 24, 2007. For ease of reference, we have set forth each comment in the Staff’s letter followed by the Company’s response. In addition, we have attached as Exhibit A to this letter, a copy of the changed pages to the signature page of Registration Statement showing the changes that the Company proposes in response to the Staff’s comments. Upon approval of the Staff, we will file an amendment to the Registration Statement (“Amendment No. 1”) incorporating these changes, and, as discussed in telephone communications with the Staff, changes to the section of the Registration Statement entitled “Selling Shareholders” to incorporate information received from the Selling Shareholders since the filing of the Registration Statement.
Comment No. 1
We will be monitoring your registration statement for resolution of your pending confidential treatment requests. All comments will need to be fully resolved before we take final action on the registration statement.
Mr. Jeffrey P. Riedler
Page
February 7, 2007
Response No. 1
Pursuant to telephone communications with the Staff, we understand that the Company’s outstanding confidential treatment requests have been granted by the Staff.
Comment No. 2
Your principal financial officer and either a controller or chief accounting officer must sign the registration statement. Your next amendment and all subsequent amendments must contain this signature. If a person acts in more than one of these capacities, the signature page must indicate all of the capacities in which they are signing. Please revise your signature page accordingly.
Response No. 2
David J. Poston is the principal financial officer and chief accounting officer of the Company. The signature page to Amendment No. 1, attached as Exhibit A hereto, reflects that Mr. Poston holds both titles.
Please do not hesitate to contact me with any questions or comments.
Very
truly yours,
/s/
Lewis S.
Malakoff
Show Raw Text
CORRESP
1
filename1.htm
[Letterhead
of Orrick, Herrington & Sutcliffe LLP]
Lewis
S. Malakoff
(206)
839-4340
lmalakoff@orrick.com
February
7, 2007
VIA
FACSIMILE (202) 772-9217 AND EDGAR
Mr.
Jeffrey P. Riedler
Assistant
Director
Division
of Corporate Finance
Securities
and Exchange Commission
100
F
Street, NE
Washington,
DC 20549
Attention:
Song P. Brandon, Esq
Re:
Targeted
Genetics Corporation
Registration
Statement on Form S-3
File
Number 333-140187
Dear
Mr.
Riedler:
This
letter sets forth the response of Targeted Genetics Corporation, a Washington
corporation (the “Company”), to the comments set forth in the Staff’s
letter dated February 2, 2007 in connection with the Company’s Registration
Statement on Form S-3 (the “Registration Statement”), filed with the
Securities and Exchange Commission (the “Commission”) on January 24,
2007. For ease of reference, we have set forth each comment in the Staff’s
letter followed by the Company’s response. In addition, we have attached as
Exhibit A to this letter, a copy of the changed pages to the signature
page of Registration Statement showing the changes that the Company proposes
in
response to the Staff’s comments. Upon approval of the Staff, we will file an
amendment to the Registration Statement (“Amendment No. 1”) incorporating
these changes, and, as discussed in telephone communications with the Staff,
changes to the section of the Registration Statement entitled “Selling
Shareholders” to incorporate information received from the Selling Shareholders
since the filing of the Registration Statement.
Comment
No. 1
We
will
be monitoring your registration statement for resolution of your pending
confidential treatment requests. All comments will need to be fully resolved
before we take final action on the registration statement.
Mr.
Jeffrey P. Riedler
Page
2
February
7, 2007
Response
No. 1
Pursuant
to telephone communications with the Staff, we understand that the Company’s
outstanding confidential treatment requests have been granted by the
Staff.
Comment
No. 2
Your
principal financial officer and
either a
controller or chief accounting officer must sign the registration statement.
Your next amendment and all subsequent amendments must contain this signature.
If a person acts in more than one of these capacities, the signature page
must
indicate all of the capacities in which they are signing. Please revise your
signature page accordingly.
Response
No. 2
David
J.
Poston is the principal financial officer and chief accounting officer of
the
Company. The signature page to Amendment No. 1, attached as Exhibit
A
hereto,
reflects that Mr. Poston holds both titles.
Please
do
not hesitate to contact me with any questions or comments.
Very
truly yours,
/s/
Lewis S.
Malakoff
Lewis
S.
Malakoff
cc:
David
J. Poston, Targeted Genetics Corporation
Stephen
M. Graham
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies
that
it has reasonable grounds to believe that it meets all of the requirements
for
filing on Form S-3 and has duly caused this Amendment No. 1 to registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the city of Seattle, state of Washington, on the 8th
day of
February, 2007.
TARGETED
GENETICS CORPORATION
By:
/s/
H. Stewart Parker
H.
Stewart Parker
President
and Chief Executive Officer
Pursuant
to the requirements of the Securities Act of 1933, this Amendment No. 1 to
registration statement has been signed by the following persons in the
capacities indicated below on the 8th
day
of
February, 2007.
Signature
Title
/s/
H. Stewart Parker
President,
Chief Executive Officer and Director
H.
Stewart Parker
(Principal
Executive Officer)
/s/
David J. Poston
Vice
President Finance and Chief Financial Officer
David
J. Poston
(Principal
Financial and Accounting Officer)
*
/s/ Jack L. Bowman
Director
Jack
L. Bowman
*
/s/ Jeremy L. Curnock Cook
Director
Jeremy
L. Curnock Cook
*
/s/ Joseph M. Davie
Director
Joseph
M. Davie
*
/s/ Roger L. Hawley
Director
Roger
L. Hawley
Director
Nelson
L. Levy
*
/s/ MICHAEL S. PERRY
Director
Michael
S. Perry
*
By:
/s/ David
J. Poston
Attorney-in-Fact
David
J. Poston